Medicine and Dentistry
Neck
100%
Chemoradiotherapy
87%
Head and Neck Cancer
76%
Squamous Cell Carcinoma
76%
Overall Survival
76%
Recurrent Disease
74%
Neck Dissection
73%
Laryngectomy
61%
Positron Emission Tomography-Computed Tomography
57%
Disease Specific Survival
52%
Oropharynx Squamous Cell Carcinoma
51%
Radiation Therapy
48%
Diseases
41%
Neoplasm
40%
Oral Cavity
38%
Head and Neck Squamous Cell Carcinoma
38%
Computer Assisted Tomography
34%
Multinodular Goitre
32%
Fluorodeoxyglucose F 18
28%
Survival Rate
26%
ErbB
25%
T Cell
25%
Sentinel Lymph Node Biopsy
25%
Histopathology
25%
Hydrogen Peroxide
25%
Selective Neck Dissection
25%
Positron Emission Tomography
25%
Obstructive Sleep Apnea
25%
Cancer of Unknown Primary Origin
25%
Thyroid Disease
25%
Clinical Trial
25%
Goiter
25%
Cervical Lymph Node Metastasis
25%
Tracheostomy
25%
Granular Cell Tumor
25%
Recurrent Laryngeal Nerve Palsy
25%
Preoperative Evaluation
25%
Clinician
25%
Recurrence Free Survival
25%
Chimeric Antigen Receptor T-Cell
25%
Nodal Metastasis
25%
Metastatic Carcinoma
23%
Local Recurrence Free Survival
22%
Ex Vivo
20%
Thyroidectomy
17%
Contralateral
17%
Sentinel Node
17%
Cancer of Unknown Primary
17%
Immunohistochemistry
17%
Disease Free Survival
16%
Pharmacology, Toxicology and Pharmaceutical Science
Head and Neck Cancer
51%
Head and Neck Squamous Cell Carcinoma
51%
Chimeric Antigen Receptor
51%
Neoplasm
35%
Immunotherapy
35%
Cytokine Release Syndrome
30%
Recurrent Disease
25%
Differentiated Thyroid Cancer
25%
Fluorodeoxyglucose F 18
25%
Head and Neck Carcinoma
25%
Clinical Trial
25%
Cadaver
25%
Polyethylene Terephthalate
25%
Skin Fistula
20%
Interleukin 4
15%
Adverse Event
15%
Chemoradiation Therapy
10%
Minimal Residual Disease
10%
Dimer
10%
Cytokine Receptor
10%
Diseases
10%
Epidermal Growth Factor Receptor
5%
Squamous Cell Carcinoma
5%
Maximum Tolerated Dose
5%
Antitumor Activity
5%
Immunogenicity
5%
SCID Beige Mouse
5%
Cyclophosphamide
5%
Receptor
5%
Retrovirus Vector
5%
Oncolytic Virus
5%
Solid Malignant Neoplasm
5%
Chill
5%
Pembrolizumab
5%
Lymphocytopenia
5%
Overall Survival
5%
Malignant Neoplasm
5%
Talimogene Laherparepvec
5%
Carcinoma
5%